Gland Pharma Ltd. - Research Center
543245 GLAND Group (A) BSE data
Add to watchlist
| Results |
Annual
|
| Statement | |
| More |
Annual results in brief
(Rs crore)
| Mar ' 24 | Mar ' 23 | Mar ' 22 | Mar ' 21 | Mar ' 20 | |
|---|---|---|---|---|---|
| Sales | 4,167.43 | 3,616.53 | 4,400.71 | 3,462.88 | 2,633.24 |
| Operating profit | 1,408.78 | 1,018.55 | 1,510.64 | 1,302.27 | 955.47 |
| Interest | 7.84 | 7.41 | 5.24 | 3.41 | 7.18 |
| Gross profit | 1,567.60 | 1,251.60 | 1,729.34 | 1,433.63 | 1,087.45 |
| EPS (Rs) | 63.34 | 47.11 | 73.78 | 60.95 | 49.88 |
Annual
results in details
| Mar ' 24 | Mar ' 23 | Mar ' 22 | Mar ' 21 | Mar ' 20 | |
|---|---|---|---|---|---|
| Other income | 166.67 | 240.46 | 223.94 | 134.78 | 139.17 |
| Stock adjustment | 87.43 | -46.92 | 36.69 | -273.49 | -6.90 |
| Raw material | 1,709.74 | 1,716.75 | 2,046.86 | 1,749.16 | 1,090.25 |
| Power and fuel | 117.20 | 124.84 | 95.05 | 74.59 | - |
| Employee expenses | 409.95 | 399.70 | 338.57 | 311.36 | 277.66 |
| Excise | - | - | - | - | - |
| Admin and selling expenses | - | - | - | - | - |
| Research and development expenses | - | - | - | - | - |
| Expenses capitalised | - | - | - | - | - |
| Other expenses | 434.34 | 403.61 | 372.90 | 298.99 | 316.76 |
| Provisions made | - | - | - | - | - |
| Depreciation | 162.11 | 146.74 | 110.30 | 98.78 | 94.59 |
| Taxation | 362.17 | 272.58 | 406.89 | 337.85 | 220.01 |
| Net profit / loss | 1,043.33 | 775.83 | 1,212.16 | 997.01 | 772.86 |
| Extra ordinary item | - | -56.46 | - | - | - |
| Prior year adjustments | - | - | - | - | - |
| Equity capital | 16.47 | 16.47 | 16.43 | 16.36 | 15.50 |
| Equity dividend rate | - | - | - | - | - |
| Agg.of non-prom. shares (Lacs) | - | - | - | - | - |
| Agg.of non promotoholding (%) | - | - | - | - | - |
| OPM (%) | 33.80 | 28.16 | 34.33 | 37.61 | 36.28 |
| GPM (%) | 36.17 | 32.45 | 37.39 | 39.85 | 39.22 |
| NPM (%) | 24.07 | 20.11 | 26.21 | 27.71 | 27.88 |
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis